ATE468107T1 - Verfahren und zusammensetzung zur behandlung von trockenen augen - Google Patents

Verfahren und zusammensetzung zur behandlung von trockenen augen

Info

Publication number
ATE468107T1
ATE468107T1 AT01982692T AT01982692T ATE468107T1 AT E468107 T1 ATE468107 T1 AT E468107T1 AT 01982692 T AT01982692 T AT 01982692T AT 01982692 T AT01982692 T AT 01982692T AT E468107 T1 ATE468107 T1 AT E468107T1
Authority
AT
Austria
Prior art keywords
film
eye
composition
mixture
emulsion
Prior art date
Application number
AT01982692T
Other languages
English (en)
Inventor
Simon Benita
Gregory Lambert
Original Assignee
Yissum Res Dev Co
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Novagali Pharma Sa filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE468107T1 publication Critical patent/ATE468107T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
AT01982692T 2001-11-01 2001-11-01 Verfahren und zusammensetzung zur behandlung von trockenen augen ATE468107T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2001/001015 WO2003053405A1 (en) 2001-11-01 2001-11-01 Method and composition for dry eye treatment

Publications (1)

Publication Number Publication Date
ATE468107T1 true ATE468107T1 (de) 2010-06-15

Family

ID=11043109

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01982692T ATE468107T1 (de) 2001-11-01 2001-11-01 Verfahren und zusammensetzung zur behandlung von trockenen augen

Country Status (11)

Country Link
EP (1) EP1441696B1 (de)
JP (1) JP2005513097A (de)
CN (1) CN100335036C (de)
AT (1) ATE468107T1 (de)
AU (1) AU2002214233A1 (de)
CA (1) CA2464243C (de)
DE (1) DE60142187D1 (de)
ES (1) ES2343512T3 (de)
HK (1) HK1067316A1 (de)
IL (1) IL161588A0 (de)
WO (1) WO2003053405A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
WO2006003519A2 (en) * 2004-07-02 2006-01-12 Novagali Pharma Sa Use of emulsions for intra: and periocular injection
EP1611879B1 (de) * 2004-07-02 2009-08-12 Novagali Pharma SA Verwendung von Emulsionen zur intra- und periocularen Injection
JP5272307B2 (ja) * 2004-07-16 2013-08-28 大正製薬株式会社 水性点眼剤
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
KR101319772B1 (ko) * 2004-11-09 2013-10-23 노바갈리 파르마 에스 에이 면역 억제제를 포함하는 안과용 유제
ES2322200T3 (es) * 2005-05-10 2009-06-17 Alcon, Inc. Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos.
US8288348B2 (en) 2005-07-13 2012-10-16 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
JP5247453B2 (ja) 2005-10-10 2013-07-24 ノバガリ ファルマ エスア プロスタグランジン含有眼科用カチオン性水中油型エマルジョン
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
PL1834635T3 (pl) * 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
DK2319517T3 (da) 2006-06-01 2013-12-09 Novagali Pharma Sa Anvendelse af prodrugs til okulær, intravenøs administration
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101130058B (zh) * 2006-08-23 2011-10-05 华北制药集团新药研究开发有限责任公司 一种环孢菌素a眼用乳剂及其制备方法
WO2008120249A1 (en) * 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2308468A1 (de) * 2009-10-08 2011-04-13 Novaliq GmbH Neuartige pharmazeutische Zusammensetzung mit einem Makrolid-Immunosuppressivum
EP2389939A1 (de) 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
DK2948134T3 (da) 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
EP3817743A4 (de) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
CN109010270B (zh) * 2018-09-03 2021-07-30 辅必成（上海）医药科技有限公司 一种阳离子材料制备的眼用乳

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe

Also Published As

Publication number Publication date
HK1067316A1 (en) 2005-04-08
WO2003053405A1 (en) 2003-07-03
AU2002214233A1 (en) 2003-07-09
EP1441696A1 (de) 2004-08-04
DE60142187D1 (de) 2010-07-01
EP1441696B1 (de) 2010-05-19
CN100335036C (zh) 2007-09-05
JP2005513097A (ja) 2005-05-12
CA2464243A1 (en) 2003-07-03
CA2464243C (en) 2010-01-19
IL161588A0 (en) 2004-09-27
CN1558751A (zh) 2004-12-29
ES2343512T3 (es) 2010-08-03

Similar Documents

Publication Publication Date Title
HK1067316A1 (en) Method and composition for dry eye treatment
DE3874479D1 (de) Loesung zur behandlung von "dry-eye"-erkrankungen.
DE69115990D1 (de) Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
JP2005513097A5 (de)
BR0011883A (pt) Composição, produto para cabelos, produto para pele, e, processo de tratamento dos cabelos ou da pele
WO2019030458A3 (fr) Emulsion moussante a haute teneur en huile et ses utilisations, notamment pour l'hygiene corporelle
BR9915536A (pt) Composição e método para cuidados com o tecido
BR9610849A (pt) Composição de limpeza pessoal e processo para a inibiçao da perda de umidade pela pele e proteção da pele
MX9803431A (es) Composicion cosmetica en emulsion de tres fases.
HUP9801443A2 (hu) Szerves polisziloxán-polioxalkilén emulgeátorral készített nagy belső fázisú emulzióval kezelt hordozóanyag
ES2161895T3 (es) Emulsiones especificas de la glandula lagrimal para aplicacion topica a tejidos oculares.
BR0212867A (pt) Emulsão de água-em-óleo, composição, e, métodos para umectar pele de mamìfero, para desinfetar tecido de mamìfero e para suprir um agente farmacêutico a um mamìfero
DE69704765D1 (de) Haarwaschmittel mit konditionierenden eigenschaften die bestimmte haarkonditionierende ester enthalten
CO4910173A1 (es) Composiciones de mascara que contienen material polimerico insoluble en agua y polimeros formadores de pelicula solu- bles en agua
CO4700410A1 (es) Base formadora de pelicula que contiene polimeros y solven- tes
TR199800437T1 (xx) Mikro em�lsiyonlar.
NO20032664L (no) Vesikkeldannende hudolje inneholdende W/O-emulgeringsmidler med en hydrofil-lipofil balanse på 2-6, fremgangsmåte for fremstilling oganvendelse derav
US4814109A (en) Method of cleaning contact lenses
MXPA05003851A (es) Composicion cosmetica de tipo emulsion de agua en aceite que contiene una sal activa desodorante y un emulsor derivado de poliolefina que lleva al menos una parte polar.
JP2007538077A (ja) 紫外線に対して保護作用のある固形石鹸
US5639450A (en) Cleansing and conditioning cosmetic composition
GB2366203A (en) Absorbent tissues providing skin barrier enhancement
ATE326207T1 (de) Kosmetische zusammensetzung zur schminkproduktenentfernung und/oder zur hautreinigung in der form einer wasser-in-öl emulsion
DE60227178D1 (de) R herstellung eines medikaments zur behandlung und/oder vorbeugung von makuladegeneration
US6718914B2 (en) Method for neutralizing offensive chemical odors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties